Ligand Pharmaceuticals Incorporated
LGNDLigand Pharmaceuticals is an American biopharmaceutical company that focuses on acquiring and developing royalty-generating assets. As of 2024, the company's portfolio included royalty rights to approximately 90 pharmaceutical products across a range of therapeutic areas. Notable products from which Ligand receives royalties include the multiple myeloma (cancer) treatments Kyprolis and Evomela, the kidney disease therapy Filspari, and the pneumococcal vaccine Vaxneuvance. The company also owns the drug development technology platform Captisol.
Drugs in Pipeline
11
Phase 3 Programs
1
Upcoming Catalysts
1
Next Catalyst
Aug 6, 2026
TomorrowMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
LGND Earnings Report
EPS Est: $1.23 | FQ end 2026-06 | Call: 2026-08-06 15:00:00
How LGND's past catalysts played out
lasofoxifene
Osteoporosis
LGD-6972-5 mg
Type 2 Diabetes Mellitus
MB07803
Type 2 Diabetes Mellitus
Budesonide + Azelastine
Seasonal Allergic Rhinitis
MB07133 300mg/m2/day
Hepatocellular Carcinoma
bexarotene
Breast Cancer
denileukin diftitox
Drug/Agent Toxicity by Tissue/Organ
PS433540
Hypertension
Aplindore
Early Stage Parkinson's Disease
irbesartan
Hypertension
Budesonide
Seasonal Allergic Rhinitis
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
lasofoxifene | Phase 3 | Osteoporosis | - | - |
LGD-6972-5 mg | Phase 2 | Type 2 Diabetes Mellitus | - | - |
MB07803 | Phase 2 | Type 2 Diabetes Mellitus | - | - |
Budesonide + Azelastine | Phase 2 | Seasonal Allergic Rhinitis | - | - |
MB07133 300mg/m2/day | Phase 2 | Hepatocellular Carcinoma | - | - |
bexarotene | Phase 2 | Breast Cancer | - | - |
denileukin diftitox | Phase 2 | Drug/Agent Toxicity by Tissue/Organ | - | - |
PS433540 | Phase 2 | Hypertension | - | - |
Aplindore | Phase 2 | Early Stage Parkinson's Disease | - | - |
irbesartan | Phase 2 | Hypertension | - | - |
Budesonide | Phase 2 | Seasonal Allergic Rhinitis | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Ligand Pharmaceuticals Incorporated's drug pipeline?→
CatalystAlert tracks 11 drug candidates in Ligand Pharmaceuticals Incorporated's (LGND) pipeline across Phase 3, Phase 2. Its lead program is lasofoxifene (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Ligand Pharmaceuticals Incorporated's next FDA catalyst?→
Ligand Pharmaceuticals Incorporated's (LGND) next tracked catalyst is a Earnings expected August 6, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track LGND biotech catalysts?→
Add LGND to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Ligand Pharmaceuticals Incorporated's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.